Source: New feed
Bone disease biotech Clementia Pharmaceuticals sets terms for $100 million IPO
Clementia Pharmaceuticals, a clinical-stage biotech focused on treating bone diseases, announced terms for its IPO on Friday. The Montreal, Canada-based company plans to raise $100 million by offering 7.2 million shares at a price range of $13 to $15.
Swiss biotech NLS Pharma's ADHD drug succeeds in mid-stage study
Swiss biotech NLS Pharma AG said on Wednesday mid-stage trial data showed that its drug to treat attention deficit hyperactivity disorder (ADHD) greatly reduced symptoms in adults, paving the way for a late-stage trial. ADHD is a chronic condition ...
and more »